Introduction
In both Menkes disease, with low levels of copper, and Wilson's disease, with elevated levels of copper, neural function is impaired (Madsen and Gitlin, 2007; Schlief and Gitlin, 2006; Cunliffe et al., 2001; Tumer and Horn, 1997) . These diseases are rare, caused by mutations in ATP7A and ATP7B, respectively. In addition to these two copper transporting P type ATPases, the uptake and tissue-specific distribution of dietary copper involves additional transporters and copper-binding chaperones (Madsen and Gitlin, 2007; Schlief and Gitlin, 2006) . Menkes patients and mottled/brindled (ATP7a Mo-br ) mice, an animal model for Menkes Disease, exhibit increased susceptibility to seizures and neurodegeneration which can be partially reversed with copper supplementation (Sheela et al., 2005) . Similar symptoms result from dietary copper deficiency; livestock consuming a copper-deficient diet develop progressive ataxic myelopathy (Madsen and Gitlin, 2007; Kumar, 2006) . In humans, acquired copper deficiency can accompany long-term parenteral nutrition or malabsorption; in addition to hematological symptoms, sensory ataxia and spastic gait may occur (Madsen and Gitlin, 2007) . Biomarkers that accurately reflect mild changes in copper status have not yet been established (Harvey and McArdle, 2008) . Copper-dependent enzymes, which evolved with the appearance of atmospheric molecular oxygen, are rare, with about a dozen in mammals (Critchton and Pierre, 2001; Ridge et al., 2008) . Peptidylglycine α-hydroxylating monooxygenase (PHM) and dopamine β-monooxygenase (DBM) are homologous copper-dependent monooxygenases, essential for the synthesis of α-amidated peptides and norepinephrine/epinephrine, respectively. The biosynthesis of amidated peptides, conserved from Planaria to humans, is compromised in mottled/brindled mice (Asada et al., 2005; Prigge et al., 2000; Steveson et al., 2003; Niciu et al., 2007) . ATP7A must interact with Atox1, a cytoplasmic copper chaperone, to transport Cu(I) from the cytoplasm into the secretory pathway (Madsen and Gitlin, 2007; Prohaska and Gybina, 2004; Puig and Thiele, 2002) .
Mutations of either PAM or ATP7A affect the vascular system and thermoregulation (Niciu et al., 2006 (Niciu et al., , 2007 Bousquet-Moore et al., 2009; Czyzyk et al., 2005; Al-Bitar et al., 2005; Ozawa et al., 2002; Maury et al., 2007) . Mice lacking PAM do not survive past E13.5; thin arterial walls and edema are apparent at E12.5 (Czyzyk et al., 2005) . Mice with a single copy of the PAM gene are viable (Czyzyk et al., Neurobiology of Disease 37 (2010) 130-140 
